$231 Million is the total value of UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's 17 reported holdings in Q2 2022. The portfolio turnover from Q1 2022 to Q2 2022 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EOCWU | ELLIOTT OPPORTUNITY II CORP | $19,600,000 | -0.6% | 2,000,000 | 0.0% | 8.48% | -16.5% | |
| IMTX | IMMATICS NV | $6,075,000 | +9.0% | 697,431 | 0.0% | 2.63% | -8.4% | |
| TXN | TEXAS INSTRUMENTS INC | $4,917,000 | -16.2% | 32,000 | 0.0% | 2.13% | -29.6% | |
| CDAK | CODIAK BIOSCIENCES INC | $2,440,000 | -54.1% | 847,108 | 0.0% | 1.06% | -61.4% | |
| PLXP | PLX PHARMA INC | $152,000 | -39.9% | 62,673 | 0.0% | 0.07% | -49.2% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $124,000 | -78.1% | 245,678 | 0.0% | 0.05% | -81.4% | |
| TFFP | TFF PHARMACEUTICALS INC | $125,000 | -10.1% | 22,066 | 0.0% | 0.05% | -25.0% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $66,000 | -12.0% | 35,714 | 0.0% | 0.03% | -25.6% | |
| APEN | APOLLO ENDOSURGERY INC | $57,000 | -39.4% | 15,601 | 0.0% | 0.02% | -47.9% | |
| POR | PORTLAND GENERAL ELECTRIC CO | $6,000 | -14.3% | 118 | 0.0% | 0.00% | -25.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-08-04
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEXAS INSTRUMENTS INC | 41 | Q3 2023 | 31.2% |
| PORTLAND GENERAL ELECTRIC CO | 38 | Q3 2023 | 0.0% |
| LEXICON PHARMACEUTICALS INC | 33 | Q3 2023 | 1.7% |
| AEGLEA BIOTHERAPEUTICS INC | 27 | Q2 2023 | 11.0% |
| APOLLO ENDOSURGERY INC | 24 | Q1 2023 | 5.6% |
| PLX PHARMA INC | 23 | Q1 2023 | 1.7% |
| VANGUARD MSCI EMERGING MKTS | 22 | Q2 2019 | 10.3% |
| VANGUARD ENERGY ETF | 22 | Q2 2019 | 8.7% |
| VANGUARD S&P 500 ETF | 21 | Q3 2023 | 11.8% |
| VANGUARD MSCI EAFE ETF | 20 | Q2 2019 | 13.1% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Taysha Gene Therapies, Inc. | September 24, 2021 | 1,156,255 | 3.0% |
| ZIOPHARM ONCOLOGY INC | February 12, 2016 | 9 | 0.0% |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-06-17 |
| 4 | 2024-06-12 |
| 4 | 2024-06-07 |
| 4/A | 2024-05-14 |
| 4 | 2024-05-01 |
| 3 | 2024-04-30 |
| 13F-HR | 2024-04-30 |
| 144 | 2024-04-29 |
| SC 13G | 2024-03-05 |
| 13F-HR | 2024-02-28 |
View UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.